Catalyst Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Catalyst Biosciences's estimated annual revenue is currently $6k per year.
- Catalyst Biosciences received $115.0M in venture funding in February 2018.
- Catalyst Biosciences's estimated revenue per employee is $333
- Catalyst Biosciences's total funding is $301.3M.
Employee Data
- Catalyst Biosciences has 18 Employees.
- Catalyst Biosciences grew their employee count by -14% last year.
Catalyst Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Financial Officer and Principal Accounting Officer | Reveal Email/Phone |
2 | Investor Relations Manager | Reveal Email/Phone |
3 | President and CEO | Reveal Email/Phone |
Catalyst Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Catalyst Biosciences?
Catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. We used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. Learn more about Our Hemophilia Program. A protease is an enzyme that cleaves target proteins. Learn more about Proteases.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
$301.3M
Total Funding
18
Number of Employees
$6k
Revenue (est)
-14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Catalyst Biosciences News
Wall Street analysts expect that Catalyst Biosciences, Inc. (NASDAQ:CBIO Get Rating) will announce earnings per share (EPS) of ($0.56) for...
SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and...
Catalyst is a research and clinical development biopharmaceutical company focused on developing protease therapeutics to address unmet medical...
CATALYST BIOSCIENCES Corporate Overview 15 November 2021 © Catalyst Biosciences Forward looking statements Certain information contained in this presentation and statements made orally during this presentation include forward-looking statements that involve substantial risks and uncertainti ...
Nasdaq: CBIO CATALYST BIOSCIENCES Corporate Overview 28 September 2021 CatalystBiosciences.com Forward looking statements Certain information contained in this presentation and statements made orally during this presentation include forward-looking statements that involve substantial risk ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.8M | 18 | -53% | N/A |
#2 | $188M | 18 | -44% | $127.8M |
#3 | $2.8M | 18 | -18% | N/A |
#4 | $1.7M | 19 | -5% | N/A |
#5 | $3.8M | 20 | -77% | N/A |
Catalyst Biosciences Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2004-10-29 | $10.3M | A | Sofinnova Ve | Article |
| 2006-02-10 | $30.0M | B | Morgenthaler Ventures | Article |
| 2008-12-04 | $40.4M | C | Essex Woodlands Health Venture | Article |
| 2012-01-09 | $7.0M | Undisclosed | Pfizer | Article |
| 2017-04-10 | $20.7M | Undisclosed | Ladenburg Thalmann & Co. Inc | Article |
| 2017-12-22 | $10.5M | Undisclosed | JonesTrading Institutional Services LLC | Article |
| 2018-02-14 | $115.0M | Undisclosed | JonesTrading Institutional Services LLC | Article |